Expert Interview
Looking into the recent decision by Pfizer to remove its sickle cell disease medication OXBRYTA (voxelotor) from the market.
Ticker(s): PFE, FULCInstitution: Boston University
- Professor of Medicine, Pediatrics, Pathology and Laboratory Medicine at Boston University, with a research focus on disorders of red blood cells
- Treats 420 patients with sickle cell
- Published 460+ articles and 3 textbooks on SCD
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
